What is BiomX Profitability Rank?
BiomX has the Profitability Rank of 2. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
BiomX's Operating Margin % for the quarter that ended in Dec. 2023 was %. As of today, BiomX's Piotroski F-Score is 2.
Competitive Comparison of BiomX's Profitability Rank
For the Biotechnology subindustry, BiomX's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BiomX's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BiomX's Profitability Rank distribution charts can be found below:
* The bar in red indicates where BiomX's Profitability Rank falls into.
BiomX Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
BiomX has the Profitability Rank of 2. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
BiomX's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
BiomX has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
BiomX (PHGE) Business Description
Traded in Other Exchanges
N/A
Address
22 Einstein Street, Floor 5, Ness Ziona, ISR, 7414003
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis.
Executives
| Assaf Oron |
officer: Chief Business Officer |
C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
| Eddie Williams |
director |
260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| Michael E. Dambach |
director |
22 EINSTEIN STREET, FLOOR 4, NESS ZIONA L3 7414003 |
| Jason M. Marks |
director |
C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807 |
| Carl L Gordon |
10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Orbimed Israel Biofund Gp Limited Partnership |
director, 10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629 |
| Chidozie Ugwumba |
10 percent owner |
158 FILMORE STREET, DENVER CO 80206 |
| Thomas Layton Walton |
10 percent owner |
P.O. BOX 1860, BENTONVILLE AR 72712 |
| Paul J Sekhri |
director |
C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588 |
| Lynne Marie Sullivan |
director |
C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139 |
| Marina Wolfson |
officer: Principal Financial Officer |
C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
| Jonathan Eitan Solomon |
director, officer: Chief Executive Officer |
C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
| Alan Charles Moses |
director |
C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
| Russell Greig |
director |
C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM |
| Gbolahan Amusa |
director |
17 STATE STREET 21 FLOOR, NEW YORK NY 10004 |
BiomX (PHGE) Headlines
Lifshitz & Miller LLP Announces Investigation of Altria Group, Inc., Chardan Healthcare Acquisition Corporation, Premier, Inc., Restoration Robotics, Inc., Vivint Solar, Inc., Waitr Holdings Inc., Xilinx, Inc., and Zscaler, Inc.
By PRNewswire PRNewswire
•
10-10-2019
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PHGE has been successfully added to your